Company Contact: John F. DeBernardis, Ph.D., President & COO
(847) 573-8025 ext. 264

Agency Contact: Ira Weingarten/Steve Chizzik
Equity Communications
(805) 897-1880

Media Contact: Deanne Eagle
(917) 837-5866

APPLIED NEUROSOLUTIONS’ BIO-MARKER DETERMINED TO BE USEFUL IN DIAGNOSING MILDLY COGNITIVELY IMPAIRED (MCI) PATIENTS

ASSAY MAY DETECT EARLY-STAGE ALZHEIMER’S DISEASE IN PATIENTS

July, 19, 2004, Philadelphia, PA--In a presentation yesterday at the 9th International Conference on Alzheimer's Disease and Related Disorders, Dr. Harald Hampel reported a biological marker referred to as p-tau231 (phosphorylation of the tau protein at amino acid 231) appears to be an excellent bio-marker for the early detection of Alzheimer’s disease (AD). This is of significance because there are, to date, no FDA-approved diagnostic tests for Alzheimer’s disease.

"Currently, it's difficult to determine if a patient has Alzheimer’s disease and whether an individual with symptoms should be started on an AD therapeutic or not," commented Dr. Hampel. "A good diagnostic would eliminate the guesswork and enable treatment to start earlier, when it could perhaps make a greater impact on the treatment of an AD patient.”

Scientists are working with different biological markers present in the brains of AD patients to determine which has the potential to actually diagnose the disease. “P-tau 231 is the best bio-marker that’s been investigated so far,” Dr. Hampel went on to say. “It is extremely sensitive in picking up patients that were only mildly cognitively impaired, and in distinguishing Alzheimer’s patients from those with other conditions and other forms of dementia.”

An assay based on p-tau 231 levels in cerebrospinal fluid (CSF) is being developed by Applied NeuroSolutions, Inc. (BB OTC: APNS). Dr. John DeBernardis, APNS President and COO, said “This study confirms our belief that p-tau 231 constitutes a core biological marker for this dreadful disease. We are moving forward with the development of a test that could determine very early if someone has Alzheimer’s disease.”

Dr. Hampel practices in the Geriatric Psychiatric Branch of the Department of Psychiatry at Ludwig-Maximilians University, Munich, Germany.

Applied NeuroSolutions is developing products to diagnose and treat Alzheimer’s disease based on a novel theory of AD cause and pathology. In partnership with Dr. Peter Davies’ scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions is developing a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy. The company is also developing a serum-based screening test for AD, as well a new class of therapeutics to treat AD.

There are currently no FDA-approved diagnostics for Alzheimer’s disease.

This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.